NorDiag continues to expand its portfolio of diagnostic sample preparation kits.  Today the company announces that its Bullet Blood Kit is available for in vitro diagnostics (IVD) use in Europe. Clinical laboratories in Europe will now be able to use this kit for clinical purposes.
 
"CE IVD (In Vitro Diagnostics) labeling is a growth driver by increasing the revenues per instrument sold and opening up for new instrument sales. CE marking enables sales to diagnostics laboratories and facilitates sales to several more customers", explains Mårten Wigstøl, CEO in NorDiag.
 
The CE IVD labeling of NorDiag's Blood sample preparation kit (for the Bullet instrument) comes after a successful completion of a validation study.
 
The Bullet Blood Kit is a sample preparation kit which can be applied in the markets for genetic diseases and HLA tissue typing (transplantation diagnostics).
 
"The Bullet Blood Kit is an important addition to our product portfolio and a key element for successful sales of Bullets in the market for genetic diseases and HLA tissue typing (transplantation diagnostics). NorDiag can now offer a set of IVD sample preparation kits for its Bullet instrument covering viruses, bacteria, genetic disorders and HLA tissue typing. It is the applications and its flexibility that drives the instrument sales, and as such NorDiag has a very good strategic position for its Bullet instrument in the molecular diagnostic market", Wigstøl comments.
 
NorDiag's medium/high throughput instrument Bullet has the capacity of up to 100 000 isolations per year.
 
Contact:
CEO Mårten Wigstøl, Phone. +47 911 65775

Read the notice in Norwegian here.